CRSP vs EDIT
CRSP and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $5.01B | $405.45M |
| P/S | 1427.0x | 10.0x |
| Revenue growth (YoY) | -90.6% | 25.4% |
| Earnings growth (YoY) | -58.8% | 32.5% |
| EBIT margin | -18933.6% | -394.9% |
| ROE | -33.3% | -152.0% |
| ROIC | -32.6% | — |
| 1y total return | -10.5% | -0.8% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: CRSP vs EDIT
| Metric | CRSP | EDIT |
|---|---|---|
| End value | $36.8K | $1.9K |
| Total return | +267.9% | -81.1% |
| CAGR | +14.1% | -15.5% |
| Volatility | 64.0% | 84.3% |
| Sharpe | 0.46 | 0.16 |
| Sortino | 0.71 | 0.24 |
| Max drawdown | -85.1% | -98.9% |
Based on 2489 common trading days, 2016-10-19 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)